1. P04: DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 CASTOR TRIAL. (5th April 2022) Authors: Sonneveld, P; Chanan-Khan, A; Weisel, K; Nooka, AK; Masszi, T; Beksac, M; Spicka, I; Hungria, V; Munder, M; Mateos, MV; Mark, TM; Levin, MD; Ahmadi, T; Qin, X; Garvin Mayo, W; Gai, X; Carey, J; Carson, R; Spencer, A Journal: HemaSphere Issue: Volume 6(2022)Supplement 2 Page Start: 12 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗